1. |
LIP G Y, TSE H F. Management of atrial fibrillation[J]. Lancet, 2007, 370(9587): 604-618.
|
2. |
HAÏSSAGUERRE M, JAÏS P, SHAH D C, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J]. N Engl J Med, 1998, 339(10): 659-666.
|
3. |
ALLESSIE M, AUSMA J, SCHOTTEN U. Electrical, contractile and structural remodeling during atrial fibrillation[J]. Cardiovasc Res, 2002, 54(2): 230-246.
|
4. |
BURSTEIN B, NATTEl S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation[J]. J Am Coll Cardiol, 2008, 51(8): 802-809.
|
5. |
ECKSTEIN J, VERHEULE S, DE GROOT N M, et al. Mechanisms of perpetuation of atrial fibrillation in chronically dilated atria[J]. Prog Biophys Mol Biol, 2008, 97(2-3): 435-451.
|
6. |
LIJNEN P J, PETROV V V, FAGARD R H. Induction of cardiac fibrosis by transforming growth factor-beta(1)[J]. Mol Genet Metab, 2000, 71(1-2): 418-435.
|
7. |
ROH J, CHANG C L, BHALLA A, et al. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor/receptor activity-modifying protein receptor complexes[J]. J Biol Chem, 2004, 279(8): 7264-7274.
|
8. |
TAKEI Y, INOUE K, OGOSHI M, et al. Identification of novel adrenomedullin in mammals: a potent cardiovascular and renal regulator[J]. FEBS Lett, 2004, 556(1-3): 53-58.
|
9. |
KINDT F, WIEGAND S, LÖSER C, et al. Intermedin: a skin peptide that is downregulated in atopic dermatitis[J]. J Invest Dermatol, 2007, 127(3): 605-613.
|
10. |
MORIMOTO R, SATOH F, MURAKAMI O, et al. Expression of adrenomedullin2/intermedin in human brain, heart, and kidney[J]. Peptides, 2007, 28(5): 1095-1103.
|
11. |
REN Y S, YANG J H, ZHANG J, et al. Intermedin 1-53 in central nervous system elevates arterial blood pressure in rats[J]. Peptides, 2006, 27(1): 74-79.
|
12. |
PAN C S, YANG J H, CAI D Y, et al. Cardiovascular effects of newly discovered peptide intermedin/adrenomedullin 2[J]. Peptides, 2005, 26(9): 1640-1646.
|
13. |
FUJISAWA Y, NAGAI Y, MIYATAKE A, et al. Roles of adrenomedullin 2 in regulating the cardiovascular and sympathetic nervous systems in conscious rats[J]. Am J Physiol Heart Circ Physiol, 2006, 290(3): 1120-1127.
|
14. |
FUJISAWA Y, NAGAI Y, MIYATAKE A, et al. Renal effects of a new member of adrenomedullin family, adrenomedullin2, in rats[J]. Eur J Pharmacol, 2004, 497(1): 75-80.
|
15. |
HAGIWARA M, BLEDSOE G, YANG Z R, et al. Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress[J]. Am J Physiol Renal Physiol, 2008, 295(6): 1735-1743.
|
16. |
YANG J H, CAI Y, DUAN X H, et al. Intermedin 1-53 inhibits rat cardiac fibroblast activation induced by angiotensin II[J]. Regul Pept, 2009, 158(1-3): 19-25.
|
17. |
MANSIA G, DE BACKER G, DOMINICZAK A, et al. 2007 ESH-ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC)[J]. Eur Heart J, 2007, 16(3): 135-232.
|
18. |
WANN L S, CURTIS A B, JANUARY C T, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation, 2011, 8(1): 157-176.
|
19. |
POTPARA T S, LIP G Y. Lone atrial fibrillation: what is known and what is to come[J]. Int J Clin Pract, 2011, 65(4): 446-457.
|
20. |
NAKAJIMA H, NAKAJIMA H O, SALCHER O, et al. Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1)transgene in the heart[J]. Circ Res, 2000, 86(5): 571-579.
|
21. |
VERHEULE S, SATO T, EVERETT T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1[J]. Circ Res, 2004, 94(11): 1458-1465.
|
22. |
BURSTEIN B, LIBBY E, CALDERONE A, et al. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences[J]. Circulation, 2008, 117(13): 1630-1641.
|
23. |
CHOI E K, CHANG P C, LEE Y S, et al. Triggered firing and atrial fibrillation in transgenic mice with selective atrial fibrosis induced by overexpression of TGF-β1[J]. Circ J, 2012, 76(6): 1354-1362.
|
24. |
CASACLANG-VERZOSA G, GERSH B J, TSANG T S. Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation[J]. J Am Coll Cardiol, 2008, 51(1): 1-11.
|
25. |
ON Y K, JEON E S, LEE S Y, et al. Plasma transforming growth factor beta1 as a biochemical marker to predict the persistence of atrial fibrillation after the surgical maze procedure[J]. J Thorac Cardiovasc Surg, 2009, 137(6): 1515-1520.
|
26. |
CHEN X, BING Z, HE J, et al. Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation[J]. Clin Cardiol, 2009, 32(6): 337-345.
|